

In 2023, Damon Runyon scientists built upon the work of their predecessors and employed cutting-edge technology to find new ways to prevent, diagnose, and treat all forms of cancer.

This year alone, Damon Runyon scientists:

- Led a clinical trial for a drug combination that induced "unprecedented" reduction of brain tumor size.
- **Discovered new antibodies** that could lead to the development of safer targeted therapies.
- Used machine learning to guide the design of next-generation CAR T cells.
- Cracked a century-old scientific mystery about how an abnormal number of chromosomes drives cancer.

AWARDS AND HONORS

Damon Runyon alumni elected to the National Academy of Sciences: Helen M. Piwnica-Worms, PhD; Michelle D. Wang, PhD; Hongkui Zeng, PhD.

Damon Runyon alumni elected to the National Academy of Medicine: Roger J. Davis, PhD, FRS; Darrell J. Irvine, PhD; Robert H. Vonderheide, MD, DPhil; Jedd D. Wolchok, MD, PhD; Hongkui Zeng, PhD.

Damon Runyon Clinical Investigator Award Committee member **Monica M. Bertagnolli, MD**, was appointed by President Biden to serve as Director of the National Institutes of Health.


Damon Runyon Physician-Scientist Training Award Committee member W. Kimryn Rathmell, MD, PhD, was appointed by President Biden to replace Dr. Bertagnolli as Director of the National Cancer Institute.

Former Damon Runyon Clinical Investigator Vinod P. Balachandran, MD, received the FNIH Trailblazer Prize for spearheading the development of the first mRNA vaccine for the treatment of pancreatic cancer, one of the deadliest malignancies.

DAMON RUNYON CANCER RESEARCH FOUNDATION

Funding brave and bold.

At the Damon Runyon Cancer Research Foundation, we fund high-risk, high-reward cancer research. We identify and enable young scientists who are brilliant, brave, and bold enough to go where others haven't.



100% OF YOUR DONATION FUNDS BRILLIANT SCIENTISTS.

We pay our low overhead with revenue from Damon Runyon Broadway Tickets and our endowment.

